5-Star Stocks Poised to Pop: Astex Pharma
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology small-cap Astex Pharmaceuticals (NAS: ASTX) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Astex's business and see what CAPS investors are saying about the stock right now.
Astex facts
Headquarters (founded) | Dublin, Calif. (1991) |
Market Cap | $190.0 million |
Industry | Biotechnology |
Trailing-12-Month Revenue | $71.8 million |
Management | Chairman/CEO Dr. James Manuso (since 2004) |
Return on Equity (average, past 3 years) | 7.5% |
Cash/Debt | $122.5 million / $0 |
Competitors | Bristol-Myers Squibb |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 330 members who have rated Astex believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those bulls, troym72, tapped the stock as an attractive growth opportunity:
[Astex] reported a good 1st quarter and if they have three more quarters like this one, the stock, now trading at $2, should be up around 30%. Solid revenue growth for 3 straight years. Past performance does not [guarantee] future gains, but I think [Astex] is on the right track to maintain growth.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Astex may not be your top choice.
If that's the case, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the newTrackPoisedToCAPS account.
The article 5-Star Stocks Poised to Pop: Astex Pharma originally appeared on Fool.com.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
